Could a gout drug and a supplement help Parkinson's? early trial begins

NCT ID NCT07170475

Recruiting now Knowledge-focused Sponsor: Fujita Health University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial will test the safety of combining two drugs—febuxostat (used for gout) and inosine (a natural substance)—in 24 adults with early-stage Parkinson's disease. Participants will take one of four dose combinations twice daily for 12 weeks, with regular blood tests and checkups. The goal is to see if the combination is safe and to measure changes in a blood marker called hypoxanthine, which may help guide future Parkinson's treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: febuxostat and inosine
What this could lead to: If successful, this safety data could point toward a new treatment approach for Parkinson's disease.
What could go wrong: This is a very early phase 1 trial with only 24 participants, so it may not lead to a proven treatment. Side effects like gastrointestinal upset or elevated uric acid are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE (PD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON'S DISEASE (PD)

Contacts and locations

Locations

Fujita Health University
RECRUITING

Toyoake, Aichi-ken, 470-1192, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.